Scenario 4: Elderly patient on multiple medications including metformin A 68-year-old with type 2 diabetes takes metformin, a proton pump inhibitor for reflux, and is starting semaglutide for additional glucose control and weight loss
- This research blend combines 100MG NAD+, 10MG MOTS-c, and 10MG 5-Amino-1MQ in a metabolic pathway-focused format studied in models involving cellular energy metabolism, mitochondrial signaling, NNMT pathway activity, NAD+-related biology, metabolic flexibility, and body-composition pathway research
In addition, BPC-157 has been studied for its potential in treating conditions like osteoarthritis, rheumatoid arthritis, and osteoporosis
So, continue injecting daily for at least three months
Simple labeling improves safety and ensures every vial is used properly